News
Public · Published
ASPN: Q3 revenue and Adjusted EBITDA beat outlook as both segments rebounded
Aspen Aerogels reported third-quarter revenue of $85.2M and Adjusted EBITDA, a measure of operating earnings, of $19.8M; both exceeded its outlook. Thermal Barrier and Energy Industrial grew sequentially, meaning from the prior quarter. Fourth-quarter revenue guidance is $60–75M, with East Providence restoration and market demand cited as uncertainties.
Published:
Updated:
What happened
Aspen Aerogels reported third-quarter revenue of $85.2M and Adjusted EBITDA, a measure of operating earnings, of $19.8M; both exceeded its outlook. Thermal Barrier and Energy Industrial grew sequentially, meaning from the prior quarter. Fourth-quarter revenue guidance is $60–75M, with East Providence restoration and market demand cited as uncertainties.
Confirmed
Global impact / market context
The stronger quarter shows both segments grew sequentially, but the lower fourth-quarter revenue outlook points to a possible near-term slowdown. If restoration work or market demand falls short, revenue could land toward the lower end of guidance, affecting earnings and cash available for operations.
Analyst inference
The article gives no share-price reaction, comparison with other companies, or explanation of the factors behind the outlook. It identifies East Providence restoration and market demand as uncertainties, so investors have limited evidence here to judge whether the quarterly beat signals durable growth.
Analyst inference
What to watch
- Compare fourth-quarter revenue with the stated guidance range; the result will show whether the third-quarter beat carried into the next period. Confirmed
- Look for updates on East Providence restoration, identified as a key uncertainty; progress or delays could affect revenue timing and operating costs. Confirmed
- Track demand across Thermal Barrier and Energy Industrial, since continued growth in both segments could support revenue while weaker demand could pressure results. Analyst inference
Evidence
- Original source link unavailable